• About Adlai Nortye

    About Adlai Nortye

    Adlai Nortye is a global clinical-stage biopharmaceutical company that is developing differentiated, innovative immuno-oncology medicines. Adlai Nortye focuses on discovering and developing important new treatments for cancer with a mission to improve patient lives by identifying and developing differentiated innovative medicines that help people live better, live longer. Through close collaborations with global partners, Adlai Nortye have successfully positioned itself in the field of immuno-oncology and have several programs ongoing from early pre-clinical to ...

    Management Team Board Of Directors Science Advisor
    • Carsten Lu, EMBA, CEO 
      ?  Founder of Adlai Nortye
      ?  Over 15 years experience of pharmaceutical R&D, manufacturing and commercialization
      ?  Bachelor of Xiamen University, EMBA of CEIBS
      ?  Responsible for strategic planning, investment and financing
    • Lars E. Birgerson, M.D., Ph.D., CDO 
      ?  Former Senior Vice President, Medical of Bristol-Myers Squibb, USA.
      ?  Physician with keen business sense and 25 years pharmaceutical industry experience in senior positions in drug development, commercial, business development and medical affairs, both globally and in the US.
      ?  Proven ability to leverage business and clinical acumen into effective solutions responsive to today’s dynamic healthcare environment.
    • XIANG YIBIN FRANK ,Ph.D., Interim CSO 
      Ph.D.of Swiss Federal Institute of Technology (ETH).

      Post-doctor of Harvard University.

      Former senior medicinal chemistry director of Sanofi Genzyme.

      ? Over 30 years of experience and success in medicinal chemistry, drug discovery and development with global pharmaceutical and biopharmaceutical companies.

      Initiated and managed multiple cross-functional programs and developed new and innovative drug therapies.
      ? Made major contributions for the identification of leading series of LTD4 antagonists, including the successful drug candidate Montelukast (Singulair).
    • YUAN RUI-RONG, M.D., President, CMO 
      ?  CMO of Eisai and BeiGene; Head of Oncology and other therapeutic Areas at Daiichi-Sankyo 
      ?  Senior Global Oncology Clinical Development Leader of Novartis
      ?  Staff Member and Attending Physician Oncology of VA NJ Health Care System, NJ Medical School
      ?  Chairman of Board Directors, Chinese American Hematologist and Oncologist Network
    • Tang Tom, M.D., MBA, SVP , Head of Development Operation 

      ?  Over  20 years experience in global clinical drug development. Completed more than 50 clinical trials.

      ?  Former chief medical officer and co-founder of Generon Inc. Former president of political affairs at Hutchison. Former head of clinical program at Pfizer.

    • Michelle Rashford, MBBS, SVP , Medical Development 
      ? Physician and leader with extensive experience in building teams within clinical development and medical affairs at a country and global level
      ? Track record in successfully leading teams to take molecules through registration and to launch
      ? Previously held senior leadership positions with BMS and Roche at local, regional and global levels
    • Dexter Fong, CFO, AICPA 
      ?  >25 years in finance/capital markets, took 3 Chinese companies public, 2 into NASDAQ and 1 into HK
      ?  Trained as an auditor and international tax consultant with various Big 4 accounting firms in HK & US
      ?  Comprehensive expertise in internal control, corporate governance, investors relations, and M&A
      ?  MBA from the University of Nevada, Reno, Masters of Accounting from the UI, Urbana Champaign
    • Carsten Lu (Chairman) 

    • Victor Yang (Director) 

    • YUAN RUI-RONG (Director) 

    • Yiming Yu (Director) 

    • Shijun Feng(Director) 

    • Yuan Tian(Director) 
    • Zhiyun Yu(Director) 
    • Gangjun Zhang(Secretary of the Board) 

    • Yufen Zhao / Academician of CAS, Professor of Xiamen University 

      · Academician of Chinese Academy of Sciences.
      · Foreign academician of the Russian Academy of International Sciences.
      · Professor of Xiamen University and Tsinghua University.

      · Founder of the "Open Laboratory of State Education Commission for the life of Organic Phosphorus Chemistry"

    • Xiaoyu Li / Professor of the University of Hong Kong 

      · Ph.D. of the University of Chicago.

      · Postdoctoral of Harvard University.

      · Professor of the University of Hong Kong.

      · Engaged in the study of life organic chemistry, chemical biology and medicinal chemistry.

      · Extensive expertise in DNA-encoded chemical libray design.

    • Junmin Quan / Professor of Peking University 

      · Ph.D. of Hong Kong University of Science and Technology.

      · Multidisciplinary background in computational chemistry, biochemistry and structural biology.

      · Extensive expertise in tumor structure biology and structure based drug design.

    • XIA WENLE / Professor of Translation Medicine, Oncology, Duke University 
      · Professor of Translation Medicine, Oncology, Duke University
      · Head of translational medicine in GSK
      · CSO of Yangtze River Pharma
      · One of inventors of EGFR/ErbB2 targeted therapies and Lapatinib
      · Responsible  for strategy of new drug R&D